Insulin discovery: A pivotal point in medical history

Falcetta, Pierpaolo; Aragona, Michele; Bertolotto, Alessandra; Bianchi, Cristina; Campi, Fabrizio; Garofolo, Monia; Prato, Stefano Del

doi:10.1016/j.metabol.2021.154941

Cited by 14 publications

(14 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As reviewed in this consensus report, encouraging healthy behaviors, DSMES, medications, devices, technologies, and organization of care all represent effective tools for the management of diabetes to reduce its morbidity and mortality. However, despite the generous approach of Banting and Best in licensing the patent for insulin for one Canadian dollar, it is not yet readily available to all people with diabetes (342,343). Recent events have focused attention on the contribution of social determinants of health and a lack of equity in the delivery of care to disparate and unfavorable outcomes.…”

Section: Place Of Technologymentioning

confidence: 99%

Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

et al. 2022

Self Cite

View full text Add to dashboard Cite

The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the previous consensus statements on the management of hyperglycemia in type 2 diabetes in adults, published since 2006 and last updated in 2019. The target audience is the full spectrum of the professional health care team providing diabetes care in the U.S. and Europe. A systematic examination of publications since 2018 informed new recommendations. These include additional focus on social determinants of health, the health care system, and physical activity behaviors, including sleep. There is a greater emphasis on weight management as part of the holistic approach to diabetes management. The results of cardiovascular and kidney outcomes trials involving sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists, including assessment of subgroups, inform broader recommendations for cardiorenal protection in people with diabetes at high risk of cardiorenal disease. After a summary listing of consensus recommendations, practical tips for implementation are provided.

show abstract

Section: Place Of Technologymentioning

confidence: 99%

Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…As reviewed in this consensus report, encouraging healthy behaviours, DSMES, medications, devices, technologies and organisation of care all represent effective tools for the management of diabetes to reduce its morbidity and mortality. However, despite the generous approach of Banting and Best in licensing the patent for insulin for one Canadian dollar, it is not yet readily available to all people with diabetes [ 342 , 343 ]. Recent events have focused attention on the contribution of social determinants of health and a lack of equity in the delivery of care to disparate and unfavourable outcomes.…”

Section: Key Knowledge Gaps and A Call To Actionmentioning

confidence: 99%

Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

et al. 2022

Self Cite

View full text Add to dashboard Cite

The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the previous consensus statements on the management of hyperglycaemia in type 2 diabetes in adults, published since 2006 and last updated in 2019. The target audience is the full spectrum of the professional healthcare team providing diabetes care in the USA and Europe. A systematic examination of publications since 2018 informed new recommendations. These include additional focus on social determinants of health, the healthcare system and physical activity behaviours including sleep. There is a greater emphasis on weight management as part of the holistic approach to diabetes management. The results of cardiovascular and kidney outcomes trials involving sodium–glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists, including assessment of subgroups, inform broader recommendations for cardiorenal protection in people with diabetes at high risk of cardiorenal disease. After a summary listing of consensus recommendations, practical tips for implementation are provided. Graphical abstract Supplementary Information The online version of this article (10.1007/s00125-022-05787-2) contains peer-reviewed but unedited supplementary material.

show abstract

“…Theme 34 discusses antitumor drugs, which inhibit tumor cell growth and induce apoptosis, providing promising therapeutic options for patients. Theme 56 discusses antidiabetic drugs and focuses on insulin, which has always been the primary pharmacological agent for treating diabetes and preventing its complications (Falcetta et al, 2022). In addition, academic inventors are also interested in antiviral drugs (Theme 23): two RNA-viruses: human immunodeficiency virus (HIV) and hepatitis C virus (HCV) received the most attention.…”

Section: Distribution and Preferred Content Of Interest Topicsmentioning

confidence: 99%

Do academic inventors have diverse interests?

Hao

2023

Scientometrics

View full text Add to dashboard Cite

Academic inventors bridge science and technology, and have attracted increasing attention. However, little is known about whether they have more diverse research interests than researchers with a single role, and whether their important position for science–technology interactions correlates with their diverse interests. For this purpose, we describe a rule-based approach for matching and identifying academic inventors, and an author interest discovery model with credit allocation schemes is utilized to measure the diversity of each researcher’s interests. Finally, extensive empirical results on the DrugBank dataset provide several valuable insights. Contrary to our intuitive expectation, the research interests of academic inventors are the least diverse, while those of authors are the most. In addition, the important position of the researchers has a certain relation with the diversity of research interests. More specifically, the degree of centrality has a significant positive correlation with the diversity of interests, and the constraint presents a significant negative correlation. A significant weaker negative correlation can also be observed between the diversity of research interests of academic inventors and their closeness centrality. The normalized betweenness centrality seems be independent from interest diversity. These conclusions help understand the mechanisms of the important position of academic inventors for science–technology interactions, from the perspective of research interests.

show abstract

Insulin discovery: A pivotal point in medical history

Cited by 14 publications

References 70 publications

Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Do academic inventors have diverse interests?

Contact Info

Product

Resources

About